The Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) study is the only ongoing nationwide antibiotic resistance surveillance program specific to ocular pathogens.
T he past 2 decades have seen an increase in antibiotic resistance among bacterial pathogens in general [1] [2] [3] [4] [5] [6] and bacterial pathogens of the eye in particular. [7] [8] [9] [10] [11] [12] [13] For instance, ocular staphylococci have developed resistance to methicillin and other antibiotic classes. 10, [13] [14] [15] [16] Infection by these and other multidrug-resistant pathogens can complicate the choice of antibiotic treatment and threaten vision. 10, 17, 18 In any bacterial infection, the causative pathogen should be identified and its antibiotic resistance profile should be determined before initiating antibacterial treatment. Current clinical laboratory methods can take several days to grow bacteria in culture and another 1 or 2 days to determine an isolate's antibiotic resistance profile. 19 In the absence of rapid diagnostic methods, physicians treat ocular infections empirically. Surveillance studies of antibiotic resistance can identify risk groups and susceptibility trends to aid in the choice of empirical treatment.
Although the World Health Organization, the US Food and Drug Administration, the Centers for Disease Control and Prevention, and other agencies monitor antibiotic resistance trends among bacteria that cause systemic diseases, ocular pathogens are rarely a target of these investigations. Resistance trends among ocular pathogens have been reported from single-center studies. 10, 13, [20] [21] [22] However, not until 2008 were results available for the first multicenter, nationwide antibiotic resistance surveillance program specific to ocular pathogens. The Ocular Tracking Resistance in US Today (TRUST) study 23 24, 25 showed an increase in methicillin resistance among S aureus isolates in subsequent years to nearly 50% in 2008, whereas methicillin resistance among coagulasenegative staphylococci (CoNS) was as high as 62.0%. Results for S pneumoniae and H influenzae appeared to be unchanged. The Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) study was initiated in 2009 to survey antibiotic resistance among S aureus, CoNS, S pneumoniae, H influenzae, and Pseudomonas aeruginosa isolates from ocular infections. 26 Like the Ocular TRUST study, the ARMOR study is a multicenter, nationwide, prospective surveillance study and provides resistance data to extend the Ocular TRUST data. Herein we present antibiotic resistance profiles and trends for more than 3000 ocular isolates collected during the first 5 years of the ARMOR study.
Methods

ARMOR Study Design
The ARMOR surveillance study has been described before. 26 Herein we report antibiotic resistance among ocular isolates collected from January 1, 2009, through December 31, 2013.
Participating sites in the United States were invited to submit isolates of S aureus, CoNS, S pneumoniae, H influenzae, and P aeruginosa cultured from various eye infections. Although endophthalmitis isolates were to be excluded, most participating laboratories lacked diagnostic information to make that exclusion. Not all sites submitted samples throughout all 5 years. Informed consent and institutional review board approval were not required for study conduct at any of the 72 sites, and Health Insurance Portability and Accountability Act compliance did not apply because samples were taken as part of routine medical care unrelated to this study and no patientidentifying information was collected.
Antibacterial Susceptibility Testing
Bacterial isolates were sent to a central laboratory (Eurofins Medinet) for species confirmation and determination of the antibiotic resistance profile. Minimum inhibitory concentrations (MICs) were determined by broth microdilution according to the Clinical and Laboratory Standards Institute methods using frozen antimicrobial microtiter panels (Thermo Fisher Scientific). (Table) . As with S aureus isolates, the newer fluoroquinolones had generally lower MIC 90 values against MSCoNS and MRCoNS.
Results
Source of Isolates
Most of the 330 S pneumoniae isolates were susceptible to the antibiotics tested, with the exception of azithromycin and penicillin (Table) . Almost all S pneumoniae isolates were susceptible to chloramphenicol and the fluoroquinolones, and besifloxacin had the lowest MIC 90 among the fluoroquinolones tested.
Among P aeruginosa isolates, resistance rates were low to those antibiotics tested, with good susceptibility to fluoroquinolones and tobramycin (Table) . However, ciprofloxacin had the lowest MIC 90 of the fluoroquinolones.
With the exception of 1 isolate resistant to azithromycin and 1 resistant to chloramphenicol, all H influenzae isolates were susceptible to all antibiotics tested. The MIC 90 values for the antibiotics tested were no greater than 0.06 μg/mL for the fluoroquinolones, 2 μg/mL for azithromycin, 0.5 μg/mL for chloramphenicol, no greater than 0.03 μg/mL for ceftriaxone, and 1 μg/mL for imipenem.
Multidrug Resistance
Methicillin-resistant staphylococcal isolates were more likely to be concurrently resistant to another drug class when compared with MS staphylococcal isolates, with P < .001 for resistance to macrolides, fluoroquinolones (using break points for ciprofloxacin), lincosamides, and aminoglycosides ( Figure 1) . Based on the high probability of concurrent resistance to an additional antibiotic class, we summarized the percentage of multidrug resistance among staphylococcal isolates. Overall, among all S aureus and all CoNS isolates, rates of multidrug resistance (resistance to ≥3 classes of antibiotics) included 472 (40.4%) and 424 isolates (42.7%), respectively, whereas among MRSA and MRCoNS, they included 428 (86.8%) and 381 (77.3%), respectively ( Figure 2 ).
Antibiotic Resistance Rates by Age of the Patient or Geography
Analysis of the mean percentage of resistance by patient age (categorized by decade of life) showed differences among staphylococci isolates (P < .001; Figure 3 ), with higher rates in elderly patients. Pairwise differences were found between S aureus isolates from patients 80 years or older compared with patients younger than 80 years, between CoNS isolates from patients 70 years or older compared with those younger than 30 years, and between CoNS isolates from patients 30 years or older compared with patients aged 10 to 29 years. Methicillin resistance, specifically, also differed by age group for S aureus and CoNS isolates (P < .001), again with the highest resistance observed in elderly patients. Resistance rates among S pneumoniae, P aeruginosa, and H influenzae isolates did not differ by age group (P ≥ .24).
Differences were found in the mean percentage of resistance by geographic region of origin for S aureus (P < .001), S pneumoniae (P = .05), and P aeruginosa (P = .01) isolates. Mean (SE) percentages of resistance among S aureus isolates were 26.0% (1.6%), 25.1% (1.1%), 24.0% (1.3%), and 17.9% (1.6%) in the South, Midwest, Northeast, and West, respectively, with a pairwise difference between the West and the other regions. Methicillin resistance paralleled that for the mean percentage of resistance, with rates of 50.0%, 45.7%, 41.0%, and 28.9% in the respective geographic regions (P < .001). For S pneumoniae, the mean (SE) percentage of resistance was 
Resistance Rates Over Time
We found few changes in resistance rates during the 5-year study period (Figure 4) . Methicillin resistance did not increase among S aureus (P = .22) or CoNS (P = .11) isolates, and we found a small decrease in resistance to ciprofloxacin among CoNS (P = .002) and MRCoNS (P = .02) isolates. Additional exploratory analysis showed a small decrease in resistance to tobramycin among CoNS isolates (P = .03). No other changes in resistance rates were noted.
Discussion
The ARMOR surveillance study provides nationwide antibiotic resistance rates among ocular isolates of S aureus, CoNS, S pneumoniae, H influenzae, and P aeruginosa, the most frequently occurring ocular pathogens. [35] [36] [37] [38] The first ARMOR analysis, based solely on isolates collected in 2009, showed that antibiotic resistance among ocular pathogens was a concern, especially among S aureus and CoNS isolates. 26 The present report expands on the 2009 data by including more than 2500 additional isolates collected during the ensuing 4 years and by testing additional antibiotics used within and outside ophthalmology. Altogether, the resistance profiles of the 3237 isolates from ocular infections collected across 36 US states were determined, making this the most robust evaluation of nationwide antibacterial susceptibility of common ocular pathogens to date. Results show that antibiotic resistance continues to be high among staphylococci, with nearly half of these isolates resistant to methicillin and a high probability of concurrent resistance among MR staphylococci to other commonly used antibiotic classes. The MRSA isolates were 16 to 18 times and the MRCoNS isolates were 4 to 8 times more likely to be resistant to ciprofloxacin, azithromycin, or tobramycin compared with the MS strains, and most of the MR staphylococci isolates were multidrug resistant. However, vancomycin remained active against these isolates. In contrast, resistance among P aeruginosa and H influenzae isolates was low against the antibiotics tested while resistance among S pneumoniae isolates was notable only for azithromycin and penicillin (based on oral break points). These findings agree with data from the latest report of the Ocular TRUST study with a single exception: cumulative rates of methicillin resistance among S aureus and CoNS isolates in our study (42.2% and 49.7%, respectively) were slightly lower than the corresponding rates from the Ocular TRUST3 study for isolates collected from 2007 to 2008 (48.1% and 62.0%). 25 Although P aeruginosa and H influenzae isolates were not evaluated in the Ocular TRUST3 study, the low resistance rates we found among H influenzae isolates are in agreement with data from the Ocular TRUST1 study. The large sample of isolates in this study allowed for analysis of resistance trends. Consistent with previous reports, 17, 26, [45] [46] [47] antibiotic resistance among staphylococci isolates was highest among elderly patients. This finding was not unexpected given that elderly patients may spend more time in nursing homes and hospitals, which are known risk factors for carrying antibiotic-resistant bacteria. Based on the reported increase in antibiotic resistance among ocular staphylococci in the years before 2009, we hypothesized that staphylococcal resistance to methicillin and ciprofloxacin would continue to increase during the 5-year study period. However, no increase in methicillin resistance was observed among staphylococci isolates in our study, and, contrary to expectations, a small decrease occurred in resistance to ciprofloxacin among CoNS and MRCoNS isolates. These findings are promising and may reflect improved antibiotic stewardship. Indeed, programs advocating judicious antibiotic use by limiting overprescription of antibiotics, cycling between antibiotic classes, and using combination therapies have led to a decrease in resistance among bacteria involved in systemic infections 1, 2, [48] [49] [50] [51] and are likely having a similar impact among bacteria causing ocular infections. Finally, analysis by geographic region revealed small differences across the United States in susceptibility among S aureus, S pneumoniae, and P aeruginosa isolates. Resistance patterns varied by species, with gram-positive isolates from the West having the lowest rates of resistance. For S aureus isolates, the highest resistance was seen in the South.
Resistance rates observed in our study were similar to rates reported for nonocular isolates from systemic infections evaluated in recent US surveillance studies with similar methods.
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For instance, the cumulative MRSA prevalence in the AWARE (Assessing Worldwide Antimicrobial Resistance Evaluation) study for isolates collected from 2009 to 2013 was 49.7%, with no longitudinal change observed during the study period. 53 Likewise, the 2013 LEADER (Linezolid Experience and Accurate Determination of Resistance) study showed a MRSA rate of 47.9%. Although the MRSA rate for MRCoNS isolates was higher in the LEADER study 52 than in our study (68.6% of 580 isolates in the LEADER study vs 49.7%), staphylococcal resistance rates for clindamycin and ciprofloxacin were analogous to those observed in our study. Penicillin resistance among S pneumoniae isolates was slightly higher in the LEADER 52 and AWARE 54 studies (17.6% of 1281 isolates in the LEADER study vs 21.1% of 3329 in the AWARE study) compared with a rate of 8.8% in our study based on oral penicillin break points. Further comparisons of S pneumoniae penicillin resistance between our study and nonocular surveillance studies 55,56 were hampered by the fact that the break points used in those studies were often not specified. Limitations of our study included potential sampling biases owing to the relatively infrequent practice of culturing bacterial pathogens, the use of systemic break points to interpret MIC data, and the choice of antibiotics tested. Systemic break points enable clinicians to choose an antibiotic for infections and to weigh the susceptibility of the bacterial pathogen against the systemic distribution of that antibiotic after oral or intravenous administration. The use of such break points may be of limited value when determining the antibiotic resistance status of ocular isolates exposed to topically applied antibiotics. However, systemic break points can be applied if one assumes that the concentration of antibiotic in the ocular tissue is equal to or greater than that achieved after systemic administration, 38 ,57,58 although higher ocular tissue concentrations may lead to overreporting of resistance. 38 We tried to include the most relevant ophthalmic antibiotics, but not all could be tested. For instance, bacitracin was not included because it is formulated as an ointment; sul- 
